CIK 0001743881
- Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,117,307
- in 3 filings, $5.1M under 10b5-1 plans
Net −$5,117,307. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-12-12 | AGUIAR ERIC Director | Grant or award · Stock Option (right to buy) | +82,878 | 82,878 | ||
| 2019-12-12 | HOMCY CHARLES J Chairman of Pharmaceuticals | Grant or award · Stock Option (right to buy) | +82,878 | 82,878 | ||
| 2019-12-12 | Cook Jennifer E. Director | Grant or award · Stock Option (right to buy) | +82,878 | 82,878 | ||
| 2019-12-12 | Satvat Ali J. Director | Grant or award · Stock Option (right to buy) | +82,878 | 82,878 | ||
| 2019-11-13 | Stolz Brian M. Chief Operating Officer | Grant or award | +22,839 | 22,839 | ||
| 2019-11-13 | Stolz Brian M. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +102,081 | 102,081 | ||
| 2019-11-13 | Stolz Brian M. Chief Operating Officer | Grant or award · Restricted Stock Units | +106,469 | 106,469 | ||
| 2019-11-13 | YAU YI CHING Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +78,148 | 78,148 | ||
| 2019-11-13 | YAU YI CHING Chief Accounting Officer | Grant or award · Restricted Stock Units | +20,376 | 20,376 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion | +34,253,561 | 34,253,561 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Purchase | +2,647,100 | $17.00 | $45.0M | 36,900,661 |
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series B Preferred Units | −81,022,727 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series C Preferred Units | −36,246,893 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series D Preferred Units | −50,446,451 | 0 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion | +6,886 | 6,886 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion | +19,318 | 26,204 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion | +59,381 | 85,585 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion | +42,100 | 127,685 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion | +35,742 | 163,427 | ||
| 2019-07-01 | SCHELLER RICHARD H Director | Exercise or conversion · Common Units | −6,886 | 0 |
Page 57 of 61 · 1,201 trades